OVARIAN SUPPRESSION WITH LEUPROLIDE ACETATE - COMPARISON OF LUTEAL, FOLLICULAR, AND FLARE-UP ADMINISTRATION IN CONTROLLED OVARIAN HYPERSTIMULATION FOR OOCYTE RETRIEVAL

被引：16

作者：

GINDOFF, PR

HALL, JL

STILLMAN, RJ

机构：

[1] Division of Reproductive Endocrinology and Fertility, Department of Obstetrics and Gynecology, George Washington University Medical Center, Washington, DC, 20037, 2150 Pennsylvania Avenue, N. W.

来源：

JOURNAL OF IN VITRO FERTILIZATION AND EMBRYO TRANSFER | 1990年 / 7卷 / 02期

关键词：

gonadotropin-releasing hormone agonist; in vitro fertilization; oocyte retrieval;

D O I：

10.1007/BF01135581

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Adjunct use of leuprolide (LA) in patients undergoing controlled ovarian hyperstimulation with human menopausal gonadotropins (hMG) was evaluated by three protocols: Group F(n=24) began LA on day 2 of the cycle and Group L(n=38) began LA on day 23 of the cycle until ovarian suppression, at which time hMG was added. Group FL (n=17) began LA on day 1 and hMG on day 3. Compared to FL, more ova were collected, more ova fertilized, and more pregnancies resulted per initiated cycle in groups achieving suppression before hMG stimulation. Fewer days were necessary to attain suppression for L vs F. After achieving suppression, patients were maintained on either 0.5 mg LA or 0.25 mg LA daily during hMG coadministration with similar results. Lower maintenance doses of LA during hMG did not decrease the amount of hMG needed but retained the benefits of LA. We recommend luteal initiation of LA to achieve suppression before hMG. © 1990 Plenum Publishing Corporation.

引用

页码：94 / 97

页数：4

共 14 条

[1] Droesch K., Muasher S., Brzyski R., Jones G., Simonetti S., Liu H., Rosenwaks Z., Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in-vitro fertilization, Fertil Steril, 51, pp. 292-297, (1989)
[2] Meldrum D., Wisot A., Hamilton F., Gutlay A., Kempton W., Huynh D., Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval, Fertil Steril, 51, pp. 455-459, (1989)
[3] Meldrum D., Chetkowski R., Steingold K., de Ziegler D., Cedars M., Hamilton M., Evolution of a highly successful in-vitro fertilization-embryo transfer program, Fertil Steril, 48, pp. 86-93, (1987)
[4] Caspi E., Ron-El R., Golan A., Nachum H., Herman A., Soffer Y., Weintraub Z., Results of in-vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone analog D-Trp 6—luteinizing hormone-releasing hormone and gonadotropins, Fertil Steril, 51, pp. 95-99, (1989)
[5] Loumaye E., Vankrieken L., Depreester S., Psalti I., Cooman S., Thomas K., Hormonal changes induced by short-term administration of a gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in-vitro fertilization and their consequences for embryo development, Fertil Steril, 51, pp. 105-111, (1989)
[6] Kreiner D., Rosenwaks Z., Short-term use of gonadotropinreleasing hormone agonist, J Vitro Fert Embryo Transfer, 5, pp. 313-314, (1988)
[7] Serafini P., Stone B., Kerin J., Batzofin J., Quinn P., Marrs R., An alternate approach to controlled ovarian hyperstimulation in “poor responders”: Pretreatment with a gonadotropin-releasing hormone analog, Fertil Steril, 49, pp. 90-95, (1988)
[8] de Ziegler D., Cedars M.I., Randle D., Lu J.K.H., Judd H.L., Meldrum D.R., Suppression of the ovary using a gonadotropin-releasing hormone agonist prior to stimulation for oocyte retrieval, Fertil Steril, 48, pp. 807-810, (1987)
[9] Katayama K., Roesler M., Gunnarson C., Stehlike, Jagusch S., Short-term use of gonadotropin-releasing hormone agonist (leuprolide) for in vitro fertilization, J Vitro Fert Embryo Transfer, 5, pp. 332-334, (1988)
[10] Meldrum D.R., Tsao Z., Monroe S.E., Braustein G.D., Sladek J., Lu J.K.H., Vale W., Rivier J., Judd H.L., Chang R.J., Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women, J Clin Endocrinol Metab, 58, pp. 755-757, (1984)

← 1 2 →